SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 03, 2011 08:16 ET

High R&D Costs Weigh on Dynavax Technologies and Marina Biotech

The Paragon Report Provides Equity Research on Dynavax Technologies & Marina Biotech

NEW YORK, NY--(Marketwire - Nov 3, 2011) - The long journey through various stages of approval can make or break biotech companies that have spent countless hours and dollars on research and development. While many companies fail, the biotech industry has been garnering the attention of investors recently, as several firms have been able to successfully bring certain products to market both domestically and abroad. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dynavax Technologies Corporation (NASDAQ: DVAX) and Marina Biotech, Inc. (NASDAQ: MRNA). Access to the full company reports can be found at:

Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. Earlier this week the company reported significant reduction of microRNA-like cytotoxic effect by incorporating a single UNA moiety in the guide strand of an siRNA when compared to an unmodified siRNA of the same sequence.

Dynavax Technologies is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax said that, based on developments to date and additional potential payments anticipated to be received or earned by year end under existing arrangements, it expects to end 2011 with approximately $50 million in cash, cash equivalents and marketable securities.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at